Health Economics›Non-small cell lung cancer squamous›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Non-small cell lung cancer squamous · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Docetaxel monotherapy Variant #02	—	R 2 921	28d	—	7.1 mo	9	R 26 293 PFS proxy	2
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	10.0 mo	2	—	2

2 of 2 regimens shown